- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05372380
A Study to Evaluate Drug-drug Interactions Between BR1017-1 and BR1017-2 in Healthy Volunteers
An Open Label, One-sequence, 3-period Study to Evaluate Drug-drug Interactions and Safety Between "BR1017-1" and "BR1017-2" in Healthy Volunteers
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Seongnam-si
-
Gyeonggi-do, Seongnam-si, Korea, Republic of, 13520
- CHA Bundang Medical Center, CHA University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Health adults aged 19 to 55 at screening.
- Male adults whose weight is ≥50kg and female adults whose weight is ≥45kg, and their body mass index (BMI) shall be between 18.0 kg/m2 and 30.0 kg/m2 BMI (kg/m2) = weight (kg) / [height (m)]2
- Those who are given detailed explanations about the trial and express their voluntary consent to participate in the trial by signing a written consent before screening procedure begins.
Exclusion Criteria:
- Those who have history of clinically significant diseases including hypersensitivity reaction, intolerability and anaphylaxis to major ingredients and other ingredients of the investigational products.
- Those who have history of clinically significant diseases related to liver (including severe hepatopathy), kidney (including severe renal impairment), digestive system (including pancreatitis), respiratory system, musculoskeletal system, endocrine system (patients with diabetic ketoacidosis, diabetic coma and precoma, type 1 diabetes, etc.), neuropsychiatric system, hemato-oncology system, cardiovascular system (including heart failure and orthostatic hypotension), etc.
- Those who have medical history of gastrointestinal system diseases (for example: Crohn's disease, peptic ulcer disease, etc.) or operations that may influence the absorption of investigational products. (However, appendectomy, hernia operation, endoscopic polypectomy and hemorrhoids/anal fissure/anal fistula surgeries are excluded.)
Those who are judged unfit for the trial at screening as follows:
- Serum ALT, AST and total bilirubin > twice the upper limit of normal levels
- e-GFR < 60 mL/min/1.73m2 (using the CKD-EPI equation)
- Positive to HBsAg, HCV Ab, HIV and Syphilis regain test (RPR)
- Systolic blood pressure of > 160 mmHg or < 110 mmHg, or diastolic blood pressure of > 100 mmHg or < 70 mmHg from vital signs measured from sitting position after 3 minutes of resting.
- Those whose test results at screening other than those mentioned in paragraph 4) above are abnormal and judged clinically significant
- Those who have participated in other clinical trials and have been administered with other investigational products in 180 days prior to the first administration of the investigational product. (The day after the last administration of any previous clinical trial's investigational product shall be counted as day 1 of the end of trial.)
- Those who took prescription drugs (including herbal medicine prescriptions) or OTC in 14 days prior to the first administration of the investigational products, or those who have not expressed their consent for drug prohibition from 14 days before the first administration of the investigational products until the end of study. (However, medicinal products may be administered if the subjects' safety and study results are considered to be unaffected according to the investigator's judgement.)
- Those who have given whole blood donation in 8 weeks before the first administration of the investigational products, who have given plasma/platelet donation or received blood transfusion in 4 weeks before the first administration of the investigational products and who have not expressed their consent for blood-donation prohibition from the first administration of the investigational products until 30 days after the final administration.
Those who have history of continuous, excessive smoking or alcohol intake in 6 months before screening (Alcohol: > 21 units/week (1unit=10g=12.5mL); Smoking: > 10 cigarettes/day), those who cannot stop smoking or caffeine intake during hospitalization or those who cannot stop drinking from 48 hours before the first administration throughout the entire study period.
☞ Amount of alcohol (g) = Amount of intake (ml) x alcoholicity (%) x 0.8* (*10g=12.5mL)
- Those who have history of diet (e.g., grapefruit juice) and health/functional food intake that can influence absorption, distribution, metabolism and excretion of the investigational products in 3 days from the first administration of the investigational product or who cannot stop the intake of such diet and food from 3 days before the first administration until the end of study.
- Those who have drug abuse (especially centrally acting drugs including sleeping pills, centrally acting pain liver, opiates or psychoactive drugs), have history of drug abuse or whose urine drug test is positive.
- Those who cannot use contraceptive measures (including sterilization operation of the subject and his/her partner, intrauterine contraceptive device and use of diaphragm or condom) that are allowed for clinical trials from the first administration of the investigational products until the last visit.
- Those who have genetic problems including galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
- Those who have history of hypersensitivity or allergy on Yellow No. 5 (Sunset Yellow FCF) ingredients.
- Female participants who are pregnant or breastfeeding, or those whose pregnancy test is positive.
- Others who are judged to be ineligible to participate in the trial by the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SEQUENTIAL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Sequence F/AE/F+AE
A total of 32 subjects will be enrolled in one sequence group.
The investigational products (IPs) will be administered according to the treatment groups(F, AE, F+AE) assigned to on sequence group in Period 1, Period 2, and Period 3.
|
Administration to the F/F+AE group: BR1017-1 will be administered 1 tablet QD, five-day repeat dose
Other Names:
Administration to the AE group: BR1017-2 will be administered 1 tablet QD, 9-day repeat dose Administration to the F+AE group: BR1017-2 will be administered 1 tablet once QD, 5-day repeat dose.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic variables - Maximum (peak) steady-state plasma drug concentration during a dosage interval(Cmax,ss) of Part A and B
Time Frame: 0~27 days after medication
|
The analysis to investigate drug-drug interaction shall be divided into two parts: Part A (Fimasartan alone vs. Fimasartan + Atorvastatin/ Ezetimibe) and Part B (Atorvastatin/Ezetimibe vs. Fimasartan + Atorvastatin/ Ezetimibe).
|
0~27 days after medication
|
Pharmacokinetic variables - Area under the plasma concentration-time curve from time zero to time t(AUCt) of Part A and B
Time Frame: 0~27 days after medication
|
The analysis to investigate drug-drug interaction shall be divided into two parts: Part A (Fimasartan alone vs. Fimasartan + Atorvastatin/ Ezetimibe) and Part B (Atorvastatin/Ezetimibe vs. Fimasartan + Atorvastatin/ Ezetimibe).
|
0~27 days after medication
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic variables - Time to reach maximum (peak) plasma concentration following drug administration at steady state (Tmax,ss) of Part A and B
Time Frame: 0~27 days after medication
|
The analysis to investigate drug-drug interaction shall be divided into two parts: Part A (Fimasartan alone vs. Fimasartan + Atorvastatin/ Ezetimibe) and Part B (Atorvastatin/Ezetimibe vs. Fimasartan + Atorvastatin/ Ezetimibe).
|
0~27 days after medication
|
Pharmacokinetic variables - Minimum steady-state plasma drug concentration during a dosage interval (Cmin,ss) of Part A and B
Time Frame: 0~27 days after medication
|
The analysis to investigate drug-drug interaction shall be divided into two parts: Part A (Fimasartan alone vs. Fimasartan + Atorvastatin/ Ezetimibe) and Part B (Atorvastatin/Ezetimibe vs. Fimasartan + Atorvastatin/ Ezetimibe).
|
0~27 days after medication
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BR-FMS-CT-119
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Addpharma Inc.Completed
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
China Academy of Chinese Medical SciencesGuang'anmen Hospital of China Academy of Chinese Medical SciencesCompletedHypertension, Resistant to Conventional Therapy | Primary HypertensionChina
-
Cytos Biotechnology AGCompletedMild Essential Hypertension | Moderate Essential HypertensionSwitzerland
Clinical Trials on BR1017-1
-
Boryung Pharmaceutical Co., LtdCompletedEssential Hypertension | Primary HypercholesterolemiaKorea, Republic of
-
Orasis Pharmaceuticals Ltd.Completed
-
University of ThessalyCompleted
-
University of Sao Paulo General HospitalCompleted
-
Chulalongkorn UniversityCompletedAllergic RhinitisThailand
-
University of Sao Paulo General HospitalCompletedOveractive Bladder SyndromeBrazil
-
Montreal Heart InstituteInstitut de Recherches Cliniques de Montreal; Royal Victoria Hospital, Canada; Queen Elizabeth II Health Sciences Centre and other collaboratorsCompletedHypertriglyceridemiaCanada
-
Yonsei UniversityCompletedObese Patients, One Lung VentilationKorea, Republic of
-
The University of Texas Health Science Center,...National Heart, Lung, and Blood Institute (NHLBI); United States Department... and other collaboratorsCompleted
-
Queen Margaret UniversityNHS LothianTerminated